Obesity Management and Redux (eBook)

Stylianos Nicolaidis (Autor)

eBook Download: PDF

1996 | 1. Auflage
144 Seiten
Elsevier Science (Verlag)
978-0-08-053791-7 (ISBN)

Infos

Redux™ is a revolutionary new anti-obesity drug that has just been approved (July 1996) by the FDA. It is the first weight management drug treatment to be launched in the United States in 20 years and is not addictive, unlike earlier drugs used for this purpose. Obesity Management and Redux™ includes a brief introduction which leads up to its discovery and includes an overview of new trends in obesity management. The book lists the pharmacological profile of the drug, given by experts involved in monitoring the effects of the drug on the brain neurotransmitters, as well as detailing the results (including safety data) of the various clinical trials.

Key Features
* Covers all aspects of a revolutionary new drug
* Lists pharmacological profile of the drug
* Includes safety data
* Projects future trends in weight management

---

Redux is a revolutionary new anti-obesity drug that has just been approved (July 1996) by the FDA. It is the first weight management drug treatment to be launched in the United States in 20 years and is not addictive, unlike earlier drugs used for this purpose. Obesity Management and Redux includes a brief introduction which leads up to its discovery and includes an overview of new trends in obesity management. The book lists the pharmacological profile of the drug, given by experts involved in monitoring the effects of the drug on the brain neurotransmitters, as well as detailing the results (including safety data) of the various clinical trials. - Covers all aspects of a revolutionary new drug- Lists pharmacological profile of the drug- Includes safety data- Projects future trends in weight management

Inhalt

Front Cover 1
Obesity Management and Redux TM 4
Copyright Page 5
Contents 14
Contributors 6
Preface 8
Introduction: History of Dexfenfluramine 12
Chapter 1. New Trends in the Management of Obesity in the United States 18
Chapter 2. The Impact of Obesity and the Introduction of Redux TM in the United States 24
Part I: Redux TM: Pharmacological Profile 28
Chapter 3. The Pharmacology of Dexfenfluramine 30
Chapter 4. Neurochemical Mode of Action of Drugs which Modify Feeding through the 5-HT System 34
Chapter 5. Dexfenfluramine: Biological Regulator of Risk Factors for Overeating 40
Part II: Methods for Assessing Neurochemical Changes and their Effect 50
Chapter 6. Advancement of Knowledge on Fenfluramine and Dexfenfluramine Effects on Brain Chemistry 52
Chapter 7. Reactive Gliosis as an Indicator of Neurotoxicity 60
Chapter 8. Dexfenfluramine Effects on Serotonin Neurons: A Long-term Immunohistochemical Analysis 66
Chapter 9. Behavioural and Other Functional Effects of Low and High Doses of Fenfluramine and Dexfenfluramine 74
Chapter 10. The Use of Pharmacokinetics in the Assessment of Dexfenfluramine Safety 82
Part III: ReduxTM: Therapeutic Efficacy 98
Chapter 11. Overview of the Clinical Data 100
Chapter 12. INDEX Study: Weight Data and Effects on Risk Factors and Comorbidities 104
Chapter 13. An 18-month Study of the Effects of Dexfenfluramine on Cognitive Function in Obese American Patients 110
Chapter 14. Fenfluramines, Obesity and Primary Pulmonary Hypertension: Risks and Benefits 116
Chapter 15. Overview of the Safety Data 122
Part IV: Benefit/Risk Ratio of the Treatment of Obesity 130
Chapter 16. Benefits and Risks of Treating Obesity 132
Chapter 17. Round Table Discussion 138

Produkt-Details

• Erscheint lt. Verlag: 21.11.1996
• Sprache: englisch
• Themenwelt: Medizin / Pharmazie ► Gesundheitsfachberufe ► Diätassistenz / Ernährungsberatung
• Themenwelt: Medizinische Fachgebiete ► Innere Medizin ► Endokrinologie
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete ► Neurologie
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie
• Themenwelt: Studium ► 1. Studienabschnitt (Vorklinik) ► Biochemie / Molekularbiologie
• Themenwelt: Technik ► Lebensmitteltechnologie
• ISBN-10: 0-08-053791-X / 008053791X
• ISBN-13: 978-0-08-053791-7 / 9780080537917